NWRN Newron Pharmaceuticals S.p.A.

SWX · CH · Healthcare · Biotechnology · newron.com

7.800CHF-3.94%Mkt Cap: 182.03M $P/E: —Today

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap182.03M USD

Enterprise Value199.83M USD

Revenue (TTM)11.89M USD

Gross Profit11.89M USD

Net Income (TTM)-15.11M USD

Revenue/Share0.52 CHF

Last Price7.800 CHF

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees27

CountryCH

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)24.48

PEG—

EV/EBITDA-7.74

EV/Revenue16.81

P/S15.94

P/B-15.31

EPS (TTM)-1.35

EPS (Forward)0.33

52W Range

7.6101% of range31.85

52W High31.85 CHF

52W Low7.610 CHF

Profitability

Gross Margin100.00%

Oper. Margin-520.54%

EBITDA Margin-217.13%

Profit Margin-69.22%

ROE118.90%

ROA-33.05%

Growth

Revenue Growth-73.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF36.92M USD

CapEx (TTM)54.78K USD

FCF Margin14.84%

FCF Yield0.97%

Net Debt7.01M USD

Net Debt/EBITDA-0.27

Balance Sheet

Debt/Equity-3.43

Current Ratio3.15

Quick Ratio2.89

Book Value/Sh-0.53 CHF

Cash/Share1.58 CHF

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CHF

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)47.13 CHF

Upside (mean)+504.3%

Target Range35.54 CHF – 71.96 CHF

35.54+504.3% to mean71.96

# Analysts4

Ownership

Shares Out.20.45M

Float18.87M

Insiders12.84%

Institutions12.49%

Technical

SMA 5011.50 (-32.1%)

SMA 20015.42 (-49.4%)

Beta0.73

S&P 52W Chg14.58%

Avg Vol (30d)84.30K

Avg Vol (10d)158.37K

Technical Indicators

RSI (14)25.8

MACD-0.9954

MACD Signal-0.6881

MACD Hist.-0.3073

BB Upper13.35 CHF

BB Middle10.41 CHF

BB Lower7.472 CHF

BB Width56.43%

ATR (14)0.6832 CHF

Vol Ratio (20d)0.70x